Randomized, observational study of long-term entecavir treatment versus other standard of care nucleos (t) ide analog therapy in nucleos(t)ide-naïve patients with chronic hepatitis B from a ‘real-world’ clinical practice setting in china

miaoyu,wukui cao,guozhong gong,jidong wang,hong zhao,lai gao,jidong xie,hong ren,lai wei,jinlin hou,jidong jia

DOI: https://doi.org/10.1016/j.jceh.2013.03.125

2013-01-01

Journal of Clinical and Experimental Hepatology

Abstract:Background: This study presents the virologic efficacy and limited safety data for up to 144 weeks of entecavir (ETV) therapy or other standard of care (oSOC) anti-HBV nucleos(t)ide analog (NUC) therapy (lamivudine, telbivudine or adefovir) in NUC-naïve CHB patients from a ‘real-world’ clinical practice setting in China. Methods: This prospective, observational cohort comprised a sub-group of 3546 NUC-naïve CHB patients enrolled in the REALM study from 50 study sites in China. Patients were randomized to ETV or oSOC, and were assessed for virologic responses and limited safety parameters over 144 weeks. Results: Overall, 3528 patients were treated (ETV: 1768; oSOC: 1760). Baseline patient characteristics were well balanced across treatment groups: approximately 80% male, 100% Asian, 64% HBeAg (+); mean HBV DNA ≈6.76 log10 IU/mL in both arms. More patients in the oSOC arm than in the ETV arm discontinued study therapy (134/1773 [8%] versus 78/1773 [4%]); the most common reasons were subject request (ETV 30 [2%], oSOC 54 [3%]), lost to follow-up (ETV 21 [1%], oSOC 39 [2%]), death (ETV 13 [<1%], oSOC 19 [1%]) and inadequate treatment response (ETV 1 [<1%], oSOC 10 [<1%]). At Week 144, 84% of ETV-treated patients had HBV DNA <50 IU/mL compared with 55% in the oSOC arm (non-completer=missing analysis). Serious treatment-related adverse events were infrequent (<1%) and comparable between both treatment arms. One patient (ETV arm) had increased alanine aminotransferase, 1 patient increased blood bilirubin (ETV arm), and 1 patient increased blood creatinine phosphokinase (oSOC arm). There were 13 deaths in the ETV arm and 21 in the oSOC arm (on treatment or during follow up). Conclusions: In a real-world setting, nucleos(t)ide naïve Chinese CHB patients treated with ETV achieved higher rates of virologic response compared with patients receiving other standard of care over 3 years of therapy.